New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareIpamorelin vs Prostamax

Ipamorelin vs Prostamax

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
Ipamorelin
Anti-Aging & Longevity
Prostamax
Summary
Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
Half-Life
2 hours
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
100–300 mcg
10 mg per day
Frequency
Once to twice daily
Daily for 10–30 days
Key Benefits
  • Increases lean muscle mass
  • Enhances fat loss
  • Improves recovery time
  • Strengthens bones and joints
  • Better sleep quality and REM sleep
  • Enhanced skin elasticity
  • Minimal impact on hunger or cortisol
  • No cortisol or prolactin spike
  • Clean GH release suitable for long-term protocols
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
Side Effects
  • Injection site irritation
  • Temporary water retention (mild)
  • Possible hunger increase (milder than GHRP-6)
  • Numbness or tingling in extremities (rare)
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
Stacks With